$325 Million Private Placement Secured By Propeling Medical Company

This funding is expected to significantly propel the company's research and development endeavors, especially the clinical development of AXPAXLI™ for wet AMD treatment. Wet AMD is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It's generally caused by abnormal blood vessels that leak fluid or blood into the region of the macula. $Ocular Therapeutix(OCUL.US)$